BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Dow
Moodys
Argus Health
Novartis
US Department of Justice
Cipla
US Army
Fish and Richardson
QuintilesIMS

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,225,294

« Back to Dashboard

Which drugs does patent 6,225,294 protect, and when does it expire?

Patent 6,225,294 protects FOSAMAX and is included in one NDA.

Protection for FOSAMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-six patent family members in forty countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 6,225,294
Title: Method for inhibiting bone resorption
Abstract:Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Inventor(s): Daifotis; Anastasia G. (Westfield, NJ), Santora, II; Arthur C. (Watchung, NJ), Yates; A. John (Westfield, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/440,577
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Device;

Drugs Protected by US Patent 6,225,294

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck FOSAMAX alendronate sodium SOLUTION;ORAL 021575-001 Sep 17, 2003 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,225,294

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,465,443 Method for inhibiting bone resorption ➤ Subscribe
5,994,329 Method for inhibiting bone resorption ➤ Subscribe
6,015,801 Method for inhibiting bone resorption ➤ Subscribe
6,544,967 Method for inhibiting bone resorption ➤ Subscribe
6,432,932 Method for inhibiting bone resorption ➤ Subscribe
6,333,316 Method for inhibiting bone resorption ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,225,294

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1265035 ➤ Subscribe
China 1166365 ➤ Subscribe
China 1602880 ➤ Subscribe
China 1299689 ➤ Subscribe
China 1602879 ➤ Subscribe
China 1919200 ➤ Subscribe
Germany 01201911 ➤ Subscribe
Germany 01201913 ➤ Subscribe
Germany 69803291 ➤ Subscribe
Austria 357921 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Julphar
Covington
Novartis
Queensland Health
Chubb
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot